Table 1.
Clinicodemographic characteristics at baseline
| Baseline characteristics | RCC (n=58) | UC (n=48) | Overall (n=106) |
| N (%) | N (%) | N (%) | |
| Age | |||
| Median, years (range) | 66 (25–82) | 72 (47–87) | 68(25-87) |
| Gender | |||
| Male | 40 (69) | 35 (73) | 75 (71) |
| Female | 18 (31) | 13 (27) | 31 (29) |
| Histology | |||
| ccRCC | 46 (79) | NA | NA |
| nccRCC | 12 (21) | NA | NA |
| UC* | NA | 47 (98) | NA |
| Non-UC† | NA | 1 (2) | NA |
| ECOG performance status | |||
| 0 | 21 (36) | 12 (25) | 33 (31) |
| 1 | 29 (50) | 28 (58) | 57 (54) |
| 2–3 | 8 (14) | 8 (17) | 16 (15) |
| RCC IMDC risk group17 | |||
| Favorable | 10 (17) | NA | NA |
| Intermediate | 39 (67) | NA | NA |
| Poor | 9 (16) | NA | NA |
| UC risk group | |||
| Platinum-sensitive group: Bajorin criteria19 | n=21 | ||
| 0 | NA | 5 (24) | NA |
| 1 | NA | 13 (62) | NA |
| 2 | NA | 3 (14) | NA |
| UC risk group | |||
| Platinum-refractory group: Bellmunt criteria18 | n=33 | ||
| 0 | NA | 2 (6) | NA |
| 1 | NA | 8 (24) | NA |
| 2 | NA | 19 (58) | NA |
| 3 | NA | 4 (12) | NA |
| Number of prior systemic therapies | |||
| 0 | 20 (34) | 22 (46) | 42 (40) |
| 1 | 26 (45) | 24 (50) | 50 (47) |
| 2 | 4 (7) | 2 (4) | 6 (6) |
| ≥3 | 8 (14) | 0 (0) | 8 (8) |
| Type of CPI regimen | |||
| PD-1/PD-L1 inhibitor monotherapy | 38 (66) | 47 (98) | 85 (80) |
| PD-1/PD-L1 +CTLA-4 inhibitor | 9 (16) | 1 (2) | 10 (9) |
| PD-1/PD-L1 +VEGF inhibitor | 11 (19) | 0 (0) | 11 (10) |
| Sites of metastases‡ | |||
| Lymph nodes | 46 (79) | 43 (90) | 89 (84) |
| Lung | 42 (72) | 24 (50) | 66 (62) |
| Bone | 16 (28) | 8 (17) | 24 (23) |
| Liver | 12 (21) | 14 (29) | 26 (25) |
| Brain | 5 (9) | 0 (0) | 5 (5) |
*Includes pure urothelial histology and mixed histology with predominant urothelial component.
†Includes one patient with a small cell bladder tumor.
‡Patients may have had more than one metastatic site.
ccRCC, clear cell renal cell carcinoma; CPI, checkpoint inhibitors; CTLA-4, cytotoxic T lymphocyte associated protein-4; ECOG, Eastern Cooperative Oncology Group; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; NA, not applicable; nccRCC, non-clear cell renal cell carcinoma; PD-1, programmed death-1; PD-L1, programmed death ligand-1; RCC, renal cell carcinoma; UC, urothelial carcinoma; VEGF, vascular endothelial growth factor.